Jaya Biosciences Secures U.S. Patent For Innovative Methods To Treat Neurological Diseases, Including Alzheimer’s, Strengthening Its Global IP Portfolio

Jaya Biosciences, Inc., a privately held early-stage life sciences company developing gene therapies targeting the central nervous system (CNS) for neurodegenerative diseases, has announced the issuance of a new U.S. patent from the United States Patent and Trademark Office (USPTO). The patent, numbered U.S. Patent No. 12,460,262 and titled “Methods of Detecting, Preventing, Reversing, and Treating Neurological Diseases,” marks a major advancement in JayaBio’s global intellectual property portfolio. It follows previous patent grants in Japan, China, and Singapore, further strengthening protection for the company’s innovative approach to lysosomal enzyme gene–based therapies for Alzheimer’s disease and other neurodegenerative disorders.

The newly granted patent covers proprietary methods for detecting, preventing, reversing, and treating neurological diseases associated with heterozygous mutations in lysosomal enzyme genes. These genetic variants have been identified as key contributors to adult-onset neurodegenerative conditions, including Alzheimer’s disease, and represent a promising therapeutic target for next-generation precision medicine approaches.

Pawel Krysiak, President and Chief Executive Officer of Jaya Biosciences, emphasized the significance of this milestone, stating, “This granted U.S. patent represents an important milestone for JayaBio. It underscores our commitment to addressing the genetic and molecular underpinnings of Alzheimer’s disease and further validates the novelty and therapeutic potential of our precision medicine gene therapy platform. The addition of U.S. patent protection reinforces our strategic position in one of the world’s most important biotechnology markets and enables us to pursue future partnerships and development opportunities.”

Eric Grinstead, Chief Commercial Officer of Jaya Biosciences, added, “The U.S. market is critical for both the scientific validation and commercialization of innovative Alzheimer’s disease therapies. This patent further secures our foundational intellectual property and strengthens our position as a leader in the emerging field of gene therapy for lysosomal dysfunction–associated neurodegeneration.”

JayaBio’s intellectual property portfolio is exclusively licensed from Washington University in St. Louis, Missouri, where researchers first discovered that mutations in lysosomal enzyme genes play a key role in adult-onset neurological diseases, including Alzheimer’s. Genetic analyses conducted at the university revealed that deleterious variants in several lysosomal enzyme genes are significantly more prevalent among individuals with Alzheimer’s compared to healthy controls, highlighting a strong genetic link between these mutations and neurodegeneration.

Professor Mark Sands, Chair of JayaBio’s Scientific Advisory Board and Professor at Washington University School of Medicine, commented, “These findings expand our understanding of the genetic factors associated with neurodegeneration in adults. Carriers of lysosomal enzyme gene defects were historically considered unaffected throughout life, but our data demonstrate a strong association between carrier status and adult-onset neurological disease. This discovery represents a paradigm shift in how we view genetic risk and intervention strategies for Alzheimer’s and related disorders.”

With the addition of this U.S. patent, Jaya Biosciences continues to build a strong foundation for the development of its gene therapy platform aimed at modifying disease progression in Alzheimer’s and other neurodegenerative diseases linked to lysosomal dysfunction.